Laboratory for Immunological and Molecular Cancer Research, Third Medical Department with Hematology, Paracelsus Medical University Salzburg, 5020 Salzburg, Austria.
Proc Natl Acad Sci U S A. 2010 Sep 14;107(37):16228-33. doi: 10.1073/pnas.1009719107. Epub 2010 Aug 30.
Aberrant anaplastic lymphoma kinase (ALK) expression is a defining feature of many human cancers and was identified first in anaplastic large-cell lymphoma (ALCL), an aggressive non-Hodgkin T-cell lymphoma. Since that time, many studies have set out to identify the mechanisms used by aberrant ALK toward tumorigenesis. We have identified a distinct profile of micro-RNAs (miRNAs) that characterize ALCL; furthermore, this profile distinguishes ALK(+) from ALK(-) subtypes, and thus points toward potential mechanisms of tumorigenesis induced by aberrant ALK. Using a nucleophosmin-ALK transgenic mouse model as well as human primary ALCL tumor tissues and human ALCL-derived cell lines, we reveal a set of overlapping deregulated miRNAs that might be implicated in the development and progression of ALCL. Importantly, ALK(+) and ALK(-) ALCL could be distinguished by a distinct profile of "oncomirs": Five members of the miR-17-92 cluster were expressed more highly in ALK(+) ALCL, whereas miR-155 was expressed more than 10-fold higher in ALK(-) ALCL. Moreover, miR-101 was down-regulated in all ALCL model systems, but its forced expression attenuated cell proliferation only in ALK(+) and not in ALK(-) cell lines, perhaps suggesting different modes of ALK-dependent regulation of its target proteins. Furthermore, inhibition of mTOR, which is targeted by miR-101, led to reduced tumor growth in engrafted ALCL mouse models. In addition to future therapeutical and diagnostic applications, it will be of interest to study the physiological implications and prognostic value of the identified miRNA profiles.
异常的间变性淋巴瘤激酶(ALK)表达是许多人类癌症的一个特征,首先在间变性大细胞淋巴瘤(ALCL)中被鉴定出来,这是一种侵袭性非霍奇金 T 细胞淋巴瘤。从那时起,许多研究都致力于确定异常 ALK 用于肿瘤发生的机制。我们已经确定了一组独特的 micro-RNAs(miRNAs),这些 miRNAs 可以用来描述 ALCL;此外,这种模式还可以区分 ALK(+)和 ALK(-)亚型,从而指向异常 ALK 诱导肿瘤发生的潜在机制。使用核仁磷酸蛋白-ALK 转基因小鼠模型以及人原发性 ALCL 肿瘤组织和人 ALCL 衍生的细胞系,我们揭示了一组重叠的失调 miRNA,这些 miRNA 可能与 ALCL 的发生和发展有关。重要的是,ALK(+)和 ALK(-) ALCL 可以通过一组独特的“oncomirs”来区分:miR-17-92 簇的五个成员在 ALK(+) ALCL 中表达更高,而 miR-155 在 ALK(-) ALCL 中表达高出 10 倍以上。此外,miR-101 在所有 ALCL 模型系统中均下调,但在 ALK(+)而不是 ALK(-)细胞系中其强制表达可减弱细胞增殖,这可能表明 ALK 对其靶蛋白的调节有不同的模式。此外,抑制 mTOR(miR-101 的靶标)可导致植入的 ALCL 小鼠模型中的肿瘤生长减少。除了未来的治疗和诊断应用外,研究所鉴定的 miRNA 图谱的生理意义和预后价值也将是很有意义的。